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ABSTRACT
Cancers of unknown primary site are metastatic cancers for which primary 
tumors are not found after detailed investigations. In many cases, the site of origin 
is not identified even on postmortem examination. These cancers are the fourth most 
common cause of cancer death. The biological events involved in the development of 
this type of cancers remain unknown. This manuscript discusses that, like metastatic 
cells, stem cells have a natural ability to migrate. A cancer of unknown primary site 
would form when deregulated, premalignant or cancerous stem cells migrated away 
from their natural tissue and gave rise to a cancer in a new site before or without 
generating a tumor in their original tissue. It is important to realize that forming 
a tumor in a tissue is not a prerequisite for stem cells to migrate away from that 
tissue. This view is in accordance with recent observations that strongly support the 
tumorigenesis model in which cancer arises from normal stem cells. Evidence has 
accumulated that cancer stem cells may play a key role in cancer progression and 
resistance to therapy. Successful treatment of cancer, including that of unknown 
primary site, may therefore require the development of therapies against cancer 
stem cells.  
INTRODUCTION
Metastasis is considered to be the process by 
which cancer cells leave a primary tumor and form one 
or several secondary tumors in other parts of the body; 
these secondary tumors are called metastatic tumors or 
metastases [1]. Histological analyses commonly show 
that cells from the primary and secondary tumors are 
similar and resemble those of the normal tissue of origin. 
In most cancer patients, the primary tumor is diagnosed 
before or at the same time than its metastases. Sometimes, 
metastatic tumors are found before standard diagnostic 
studies reveal the location of the primary site. But other 
times, metastatic tumors are found, and a primary tumor 
is not identified after detailed diagnostic investigations. 
These tumors generally contain poorly differentiated or 
undifferentiated cells, which makes the identification of 
the tissue of origin difficult. In some cases, the histology 
or location of the tumor strongly suggest a specific 
primary site; however, exhaustive investigations also 
fail to identify a primary tumor. These cancers are called 
cancers of unknown primary (CUP), cancers of unknown 
primary site, cancers of unknown origin, or occult primary 
cancers [2-4]. 
Cancer of unknown primary site is a heterogeneous 
group of cancers for which the anatomical site of origin 
remains occult after detailed investigations. In 15-
25% of cases, the primary site is not identified even on 
postmortem examination. Cancer of unknown primary site 
accounts for approximately 3-5% of all human cancers. It 
is the seventh to eighth most frequent malignancy, and it 
is the fourth most common cause of cancer death in both 
sexes. In a third of patients diagnosed with CUP, three 
or more organs are involved at the time of diagnosis. 
The pattern of metastasis (frequency and location of 
metastases) in patients diagnosed with CUP may be 
significantly different from that in patients with known 
primary tumors. Most cancers of unknown primary site 
show an aggressive behavior and are incurable [2-4].
Since the site of the primary tumor usually dictates 
the treatment and expected outcome, the inability to 
identify a primary site raises concern among oncologists 
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and patients. Current research and clinical efforts are made 
to develop and use knowledge and technology to locate 
the primary tumor or, at least, to reliably predict the tissue 
of origin. Primary and metastatic tumors commonly have 
similar expression profiles and molecular signatures. This 
makes immunohistochemical testing and tissue-of-origin 
molecular profiling useful tools for predicting the tissue 
of origin [3]. Recently, Polak et al. compared mutation 
densities to epigenetic profiles of normal and cancer cells 
from different tissues, and reported findings suggesting 
that the tissue of origin of a cancer may be accurately 
predicted based on the distribution of mutations along its 
genome [5]. Predicting the tissue of origin is particularly 
important for the types of CUP that respond relatively 
well to specific therapies (approximately 20% of CUP). 
When these cancers are ruled out, it usually becomes 
less important to find or predict the primary site. For 
example, in an analysis of several post-mortem cohort 
studies, the potential primary tumor was identified in 
73% of patients, and the most common primaries were 
lung (27%) and pancreatic (24%) tumors [6]. The five-
year relative survival rate for patients with lung cancer and 
pancreatic cancer with distant metastases is 4% and 2%, 
respectively [7]. Therefore, the identification of a primary 
site in patients with these two types of cancer would not 
have changed much their outcome.
Understanding the existence of cancers of 
unknown primary site and the mechanisms involved in 
their formation may lead to the development of better 
treatments. These treatments may be useful not only for 
patients with these cancers, but also for patients with other 
metastatic cancers. Currently, it is generally accepted that 
CUP exists because of our inability to identify the primary 
tumor due to clinical or technological inefficiencies, or 
because the primary tumor regresses or stays dormant after 
spreading the cancer cells that generate the metastases [2-
4]. Some studies have shown molecular features shared 
by cancers of unknown primary origin. For example, 
a recent analysis of 1806 cases of cancer of unknown 
primary site has revealed that TP53 is the most commonly 
mutated gene in these cancers [8]. However, the biological 
events that allow the primary site to remain occult after the 
development of metastases remain unknown [2-4].
Stem cells have a natural ability to migrate
Recent evidence suggests that the biological events 
occurring during the development of metastasis are rather 
similar to those occurring during embryonic development. 
During embryogenesis, stem cells can invade tissues, 
move through the interior of the embryo, travel long 
distances, and establish in new places to participate in the 
formation of organs and tissues [9-11]. During metastasis, 
cancer cells can invade tissues, move through the 
lymphatic and circulatory systems, travel long distances, 
and establish in new tissues to form tumors [1,12]. The 
activation of the epithelial-mesenchymal transition (EMT) 
and the mesenchymal-epithelial transition (MET) seems 
to play a critical role in the migration ability of both 
embryonic stem cells and metastatic cells. The activation 
of these transition programs involves profound changes 
in cell morphology and behavior, including changes in 
cytoskeleton structure, cell polarity, cell-cell contact and 
extracellular matrix degradation. Recent data suggest 
that EMT activation is an early event in carcinogenesis, 
and that there is a crosstalk among EMT activation, the 
acquisition of molecular and functional traits of cancer 
stem cells, and the inactivation or mutation of p53 
[9,10,13-15].
The migration ability of stem cells is repressed after 
embryonic development, but probably reappears during 
pathological conditions. Adult stem cells (also known 
as tissue stem cells) can increase their migratory activity 
when their microenvironment is altered [16]. These cells 
play a key role in tissue damage repair; tissue injury 
activates developmental programs that activate adult stem 
cell migration to the site of damage [17]. Interestingly, 
tissue injury may increase cancer risk [18-21]. Adult 
stem cells may also increase their migratory potential 
after accumulating specific DNA alterations. These 
premalignant stem cells may also acquire additional DNA 
alterations and become cancer stem cells (CSCs). These 
cancer cells seem to play a key role in tumor metastasis 
[12,22]. It has been proposed that CSCs can be stationary 
(which establish tumor growth) or mobile (which lead to 
tumor metastasis) [23], and these two populations of CSCs 
have been found in human cancer tissues [24].
The migration ability of stem cells can explain the 
existence of cancers of unknown primary site. A cancer 
of unknown primary site would form when deregulated, 
premalignant or cancerous stem cells migrated away from 
their natural tissue and gave rise to a cancer in the new 
site before or without generating a tumor in their original 
tissue. It is important to realize that forming a tumor in a 
tissue is not a prerequisite for stem cells to move away 
from that tissue; this is probably the key to understand the 
existence of cancer of unknown primary site. Stem cells 
can migrate from their natural tissue and initiate a cancer 
in the new site before generating a detectable tumor in 
their natural tissue. In this case, the primary tumor could 
be identified after some time. However, stem cells can also 
migrate away from their natural tissue without generating 
a cancer there. In this case, the “primary tumor” would 
never exist. This can explain why the primary site is 
not identified even on postmortem examination in many 
patients with these cancers (Figure 1).
Cancer may arise from normal stem cells
This explanation for the existence of cancers of 
unknown primary site implies that these cancers arise 
either from normal stem cells or from non-stem cells that 
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have activated stem cell programs. Here I discuss evidence 
suggesting that cancer, including that of unknown primary, 
may originate in normal stem cells.
Numerous experimental investigations have been 
conducted to identify the cells of origin in cancer [25]. 
These investigations both challenge and support the idea 
of cancer arising from stem cells [25-27]. For example, 
experimental data suggest that progenitor cells can 
dedifferentiate and develop stem-like properties; this has 
led to the proposal that cancer may start in progenitor 
cells [26]. Experimental data have also shown that long-
term passaged stem cells become cancer cells in culture 
and generate solid tumors when injected into rodents 
[28]. It is important to note that all these investigations 
involve experimental manipulation. As discussed 
elsewhere [28], stem cells are defined in terms of their 
functional properties: long-term self-renewal capacity 
and differentiation potential. This presents an inherent 
problem because these properties can only be assessed 
by experimental manipulation, and experimental 
manipulation probably alters the functional properties of 
these cells. Just culturing stem cells in vitro may induce 
profound changes in their proliferative rates, cellular fate 
or behavior. In vivo, stem cells are established in niches. 
Stem cell niches are microenvironments that protect the 
stem cells and regulate the way they behave. The stem 
cell niche provides support and signals that regulate 
their proliferative rates, self-renewal, differentiation and 
migration activities [16]. Stem cells cultured in vitro are 
deprived of their niches, which may completely change 
their biological behavior. This may explain, for example, 
that stem cells that are resting in vivo may become 
proliferative in cell culture. In addition, the studies 
aimed at identifying the cells of origin in cancer usually 
involve a genetic or chemical manipulation of the cells 
[25]. We should therefore interpret the findings of these 
experimental studies cautiously.
 Solid biological concepts may provide more reliable 
information on the cells of origin in cancer. The long 
lifespan and self-renewal capacity of stem cells support the 
idea of cancer arising from these cells. These biological 
properties indicate that stem cells have the opportunity to 
accumulate sufficient DNA alterations to generate cancer 
cells [29]. Three reasons are commonly used to challenge 
this idea. First, cancer probably starts in cells with high 
proliferative rates, and the adult stem cells of some 
tissues do not divide often. Second, stem cells represent a 
small population within a tissue, and the probability of a 
stochastic carcinogenic hit is lower in a small population 
than in a large population. Third, carcinogenesis depends 
on the acquisition of advantageous cell phenotypes, 
and these phenotypes are less likely to occur when a 
cell self-renews than when a cell differentiates [26]. 
Recognizing that life starts before birth makes the first 
two challenging reasons difficult to accept. First, stem 
cells divide very actively during embryonic development. 
Figure 1: The migration ability of stem cells can explain the existence of cancer of unknown primary site. A cancer of 
unknown primary site would form when deregulated stem cells, premalignant stem cells or cancer stem cells migrated away from their 
natural tissue (primary site) and formed a tumor in another tissue (secondary site) before or without generating a tumor in their primary 
location. Thick arrows represent the probably most common pathway for metastasis. Curved arrows represent self-renewal capacity. See 
text for further details. 
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During this relatively short period, one cell (zygote) 
gives rise to the billions of cells that form a developed 
embryo [30]. The genome of the adult stem cells at the 
time of birth has already been copied many times, and 
probably contains many heritable alterations in relation 
to that of the zygote. In some adult stem cells, these 
alterations may contribute to a possible carcinogenesis 
process occurring later in life. They may also increase 
their proliferative rates during adulthood. Second, stem 
cells are the only cell population at the initial stages of 
embryonic development. Stem cells are therefore the only 
cells exposed to the acquisition of carcinogenic damage 
during this period of intense mitotic activity. Third, 
the chance of a carcinogenic hit during cell division is 
probably similar in a cell that self-renews to produce two 
undifferentiated daughter cells than in a cell that gives rise 
to two differentiated daughter cells. The limited fidelity of 
DNA polymerases is known to be an important source of 
DNA mutations during cell division. DNA polymerases 
probably insert similar levels of incorrect nucleotides in 
the DNA of the daughter cells when copying the DNA of 
a stem cell that self-renews than when copying the DNA 
of a progenitor cell that differentiates. The acquisition of 
advantageous cell phenotypes is probably relevant at late 
stages of carcinogenesis; however, this factor is unlikely 
to determine what type of cell is more prone to acquire the 
first carcinogenic hit. Overall, the idea of cancer arising 
from normal stem cells has a solid biological basis.
Figure 2: The stem cell model of cancer can explain the age distribution of cancer. A) Age is the most important cancer risk 
factor, and cancer incidence increases with age. B) Stem cells self-renew, have a long lifespan, and are the only cells that transmit the DNA 
of the zygote to the cells we have at the time of death. Stem cells can differentiate into progenitor cells and eventually into differentiated 
cells. C) Stem cells can acquire and accumulate DNA alterations during our whole life. Because progenitor cells lack an innate ability 
to self-renew and have a relatively short lifespan (until they fully differentiate), they can acquire and accumulate DNA alterations only 
during relatively short periods of our life. The model in which cancer arises from stem cells fits the age distribution of cancer better than 
the model in which cancer initiates in progenitor cells. Curved arrows represent self-renewal capacity.  SC: stem cell; PC: progenitor cell; 
DC: differentiated cell.
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It is important to recognize that the first carcinogenic 
hit does not necessarily have to be the first mutation 
occurring in one of the genes whose involvement in cancer 
development is understood at a given moment. The first 
carcinogenic hit should be referred to as the first heritable 
change (e.g., DNA mutation, epigenetic change or 
chromosome alteration) that participates in the formation 
of a cancer. The first hit may be a DNA alteration with 
biological implications not yet understood, and may occur 
in a non-coding DNA sequence [31].
Observational studies do not involve experimental 
manipulation and may provide reliable information 
regarding the cells of origin in cancer. Numerous 
observational studies have shown that age is the most 
important cancer risk factor [7,32-35]. For example, 
recent data show that approximately 4.4% of people 
under 50 years old are diagnosed with cancer in the US; 
this percentage increases to 6.3% in people in their 50s, 
to 12.5% in people in their 60s, and to 31.2% in people 
older than 70 years old [7]. These studies indicate that our 
cancer risk increases during our whole life. Stem cells are 
the only cells that transmit the genome of the zygote to the 
cells we have at the time of death and, therefore, are the 
only cells that can acquire and accumulate DNA alterations 
during our whole life. Progenitor cells lack an innate 
ability to self-renew and have a relatively short lifespan. 
Progenitor cells, therefore, can acquire and accumulate 
DNA alterations only during relatively short periods of our 
life. If cancer arose from progenitor cells, a progenitor cell 
produced when we are 10 would have the same probably 
to initiate a cancer than a progenitor cell produced when 
we are 30 or 50. After a lag period of e.g. 20 years, our 
risk of having cancer would be similar in our 30s, 50s 
or 70s. Cancer statistics show otherwise. The stem cell 
model of cancer fits the age distribution of cancer better 
than the progenitor cell model of cancer (Figure 2). Cancer 
statistics also show that cancer incidence decelerates late 
in life, i.e., cancer incidence rises with age, but the rise 
occurs more slowly in later years. Interestingly, an overall 
decline in tissue regenerative potential also occurs in 
later years, which is attributed to a decline in stem cell 
functionality with age [36].
The observation that some tissues give rise to 
cancers millions of times more often than other tissues 
has long puzzled cancer researchers. This observation 
cannot be explained by different levels of exposure 
to carcinogens. For example, melanocytes and basal 
epidermal cells of the skin are exposed to similar levels of 
the same carcinogen (ultraviolet radiation); however, basal 
cell carcinomas are much more common than melanomas 
[37]. C. Tomasetti and B. Vogelstein [37] have recently 
provided an explanation for this observation. They found 
that there exists a highly positive correlation (Spearman’s 
rho = 0.81; P < 3.5 × 10−8) between the number of normal 
stem cell divisions in a tissue and the lifetime risk for 
developing cancer in that tissue. This striking correlation 
applied to 31 cancer types and extended across five orders 
of magnitude. No environmental or inherited factor is 
known to correlate so strongly with cancer incidence 
across tissues [37]. In simple terms, the data provided by 
C. Tomasetti and B. Vogelstein indicate that if the normal 
stem cells from one of our tissues divide once, our cancer 
risk in that tissue is approximately 1X. If they divide 
10 times, our cancer risk is 10X. If they divide 1,000 
times, our cancer risk is 1,000X. And if the normal stem 
cells from one of our tissues divide 100,000 times, our 
cancer risk in that tissue is approximately 100,000X. This 
strongly suggests that the main reason we have cancer is 
that our normal stem cells divide. A reasonable way to 
interpret this is that cancer arises from normal stem cells. 
The other option would be difficult to accept. If cancer 
arose and developed in non-stem cells, we would have 
to admit that stem cell division is the main determinant 
for the neoplastic transformation of non-stem cells. This 
would mean that any time a particular cell divides, another 
cell is transformed. It makes much more sense to think that 
normal stem cells acquire and accumulate carcinogenic 
damage when they divide than to think that their division 
inflicts carcinogenic damage on non-stem cells.
CONCLUDING REMARKS
Currently, metastasis is considered to follow the 
next sequence: invasion and intravasation of cancer 
cells from the primary tumor, dissemination through the 
circulation, extravasation in different organs, survival on 
arrival, settlement into latency, reactivation, and overt 
colonization with generation of a new macroscopic 
tumor [1,12]. If metastasis is the process by which cancer 
cells leave a primary tumor and form secondary tumors 
in other locations [1,12], the existence of cancers of 
unknown primary site can be seen as a biological mystery 
[4]. However, if we challenge this prevailing view and 
consider that the cells that leave the primary tissue do 
not necessarily have to be cancer cells from a tumor, the 
existence of cancers of unknown primary site becomes a 
plain biological process. The injection of morphologically 
normal breast cells from genetically engineered mice into 
the tail veins of other female mice resulted, after oncogene 
induction, in the formation of tumors in the lungs but not 
in the breast [38]. Although these cells were genetically 
and chemically manipulated, these experiments show that 
the formation of a primary tumor is not a requisite for the 
formation of metastatic tumors. Metastasis should be seen 
as the process by which cells from a tissue form tumors 
in other tissues. All cancers, including those of unknown 
primary site, fit in this simple definition (Figure 1). 
The term occult primary tumor should be avoided 
in the absence of a primary tumor, because it implies 
that the tumor exists and is hidden. This term may cause 
anxiety among clinicians and patients, who may think that 
their evaluation has been deficient. In many cancers of 
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unknown primary site, primary tumors are never found. 
In an analysis of post-mortem cohort studies, primary 
tumors were not identified in 27% of patients [6]. In some 
cancers of unknown primary site, the histology or location 
of the tumor strongly suggest a specific primary site. For 
example, the identification of adenocarcinomas in isolated 
unilateral axillary lymph nodes in women with CUP 
strongly suggests that these tumors originate in the breast. 
Breast tumors commonly metastasize to this site, and 
this type of CUP is found almost exclusively in women. 
However, breast tumors were not identified in 28% of 
446 women who were diagnosed with this type of CUP 
and underwent mastectomy and subsequent histological 
analysis [2,39]. The terms primary tumor and secondary 
tumor should also be avoided in the absence of a primary 
tumor. In CUP patients, the terms primary site and tumor 
of unknown primary site should be used instead, at least 
until a possible primary tumor is eventually found.
Not all cells can leave their natural tissue and form 
tumors in other locations. The cell needs migration ability 
to leave its tissue and reach the new one, proliferative 
capacity to accumulate enough DNA alterations to produce 
a cancer cell, and self-renewal capacity so that its only 
fate is not the generation of non-dividing differentiated 
cells. Stem cells constitute the only cell population with 
these three biological properties under physiological 
conditions. This implies that cancers of unknown primary 
site originate in stem cells, or in non-stem cells that have 
acquired these biological properties.
Non-stem cells (e.g., progenitor cells) can acquire 
DNA alterations. In some cases, these alterations may 
result in the activation of stem-cell programs, and may 
even determine whether or not we will eventually have 
a cancer. But this does not imply that these cancers arise 
from non-stem cells, because the stem cells from which 
they derive may have DNA alterations that also participate 
in the formation of these cancers. Three lines of evidence 
discussed in this manuscript suggest that the majority of 
human cancers may arise from normal stem cells. First, 
cell division is a major source of DNA alterations, stem 
cells constitute the only cell population during the initial 
period of life (early stages of embryonic development), 
and stem cells divide very actively during this period. 
This means that it is likely that stem cells acquire DNA 
alterations during embryonic development, which may 
play a role in a possible carcinogenic process occurring 
later in life. Because the first carcinogenic hit may be 
a DNA alteration with biological implications not yet 
understood, we cannot exclude the possibility that an 
important percentage of cancers may start before birth. 
Second, stem cells are the only cells that transmit our DNA 
during our whole life, and the risk of developing cancer is 
known to increase during our whole life. The observation 
that cancer risk increases with age can be better explained 
by a model in which cancer initiates in stem cells than 
by a model in which cancer initiates in progenitor cells 
(Figure 2). Third, if cancer initiated and developed in 
non-stem cells, the presence or biological activity of 
stem cells in a tissue would not significantly modify the 
risk of developing cancer in that tissue. However, recent 
observations strongly suggest that the number of normal 
stem cell divisions in a particular tissue seems to be the 
main determinant for developing cancer in that tissue [37].
If cancer arises from normal stem cells, these cells 
would eventually become cells with the ability to generate 
tumors, i.e., cancer stem cells (CSCs). In other words, a 
CSC would be a stem cell that has developed a long-term 
ability to generate heterogeneous tumor populations. This 
view of CSCs considers their origin (normal stem cells), 
their self-renewal capacity (ability to copy themselves 
during long periods), and their differentiation potential 
(ability to generate heterogeneous cellular populations). 
These cells would develop in all types of cancer, including 
those in which they have not yet been identified. Some 
CSCs would self-renew, and others would differentiate 
and give rise to cells without self-renewal ability 
(progenitor cancer cells) and without self-renewal ability 
and proliferative capacity (differentiated cancer cells). 
All these cancer cells would contribute to the cellular 
heterogeneity of tumors [40]. A CSC located in a tissue 
different from that of the normal stem cell from which 
it originates would be a metastatic cancer stem cell. This 
view implies that the stem cell can migrate to the new 
tissue before or after becoming a CSC. It is important to 
realize that the process by which a normal cell becomes a 
cancer cell does not necessarily have to start and complete 
in the same tissue.
CSCs seem to play a crucial role in tumor growth, 
metastasis and resistance to therapy [22,41]. Successful 
cancer therapy may therefore require the elimination of 
these cells. Experimental data indicate that non-stem 
cancer cells may dedifferentiate into CSCs [27,42-45]. 
This means that, if we only eliminate CSCs, non-stem 
cancer cells may generate new CSCs and repopulate the 
tumor [42]. Successful therapy may therefore require the 
elimination of CSCs and their progeny. Clinical trials are 
ongoing to test the efficacy of drugs targeting CSCs, alone 
and in combination with conventional drugs targeting non-
stem cancer cells [46].
Anti-CSC therapies might show efficacy in a 
wide range of CUP patients. Histological analyses of 
many tumors from CUP patients show populations of 
poorly differentiated or undifferentiated cells. Since 
stem cells constitute the less differentiated cell type, the 
undifferentiated cells of these tumors might be CSCs; 
these cells would play a role in the known aggressive 
behavior and therapeutic resistance of these cancers. In 
addition, the prognosis for most CUP patients is poor even 
when the primary site is predicted. The identification of 
a possible primary site allows CUP patients to be treated 
with the therapies used in metastatic patients with known 
primary tumors. These therapies, however, are generally 
Oncoscience473www.impactjournals.com/oncoscience
not curative. CUP patients might therefore benefit from 
participating in clinical trials evaluating new anti-CSC 
treatments.
The lack of effective treatments for most CUP 
patients should not justify their inclusion in clinical studies 
testing experimental therapies not properly validated 
in preclinical models. Clinical trials in oncology have 
the highest failure rate compared with other therapeutic 
areas [47]. Most of the drugs that show remarkable 
anticancer effects in preclinical models fail when tested 
in cancer patients. Part of these failures may be due to 
poor preclinical designs, in which the needs of cancer 
patients are often misunderstood [48]. Cancer patients do 
not need new drugs that target their cancer cells at low 
concentrations if they also target their normal cells at 
similar concentrations. Cancer patients will probably not 
benefit from drugs that induce marked tumor shrinkages 
in animal models that do not represent their disease. 
Cancer patients need drugs that improve the efficacy of 
the existing treatments. Selectivity (in vitro) and survival 
rate (in vivo) are probably the most reliable parameters 
to predict drug efficacy in cancer patients [48]. In vitro, 
the new treatment should improve the selectivity of the 
existing drugs when tested in cancer cells versus a variety 
of normal cells (non-stem cells and stem cells from a 
variety of healthy tissues) [48-50]. The efficacy of a 
new drug combination should be assessed by testing in 
cancer cells versus non-malignant cells if it improves the 
selectivity of the standard treatment, and not by testing in 
cancer cells if its cytotoxicity is enhanced (potentiation 
factor) or synergistically increased (combination index) 
in relation to the cytotoxicity induced by each drug 
individually [48]. In vivo, the new treatment should 
improve the survival rate of the existing therapy in 
animal models representative of the patients who would 
eventually receive the new drugs [48]. Selecting animal 
models of metastasis is essential if the new drugs are 
intended for CUP patients or for other patients with 
metastatic disease. It should be noted that CSCs may 
constitute a minority population within a tumor (perhaps 
1 to 3% [46]), and that a remarkable tumor shrinkage may 
leave the whole CSC population unaffected.
In summary, evidence suggests that the majority 
of human cancers may originate in normal stem cells. 
Cancers of unknown primary site probably exist because 
stem cells (deregulated, premalignant or cancerous) 
migrate away from their natural tissues and generate 
tumors in other locations before or without generating 
tumors in their natural tissues. Metastasis should be 
considered as the process by which cells from a tissue give 
rise to tumors in other locations.
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